about
Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.[Significance of anemia as an independent prognostic factor in patients with renal cell carcinoma].Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.Sympathetic skin response in patients with erectile dysfunction.Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancerSignificance of collagenase 3 (matrix metalloproteinase 13) in invasive bladder cancer: correlation with pathological parameters[Effectiveness of bisphosphonates in advanced prostate cancer]Telomere length on bladder washing samples from patients with bladder cancer correlates with tumor characteristics flow cytometry method for quantitative fluorescence in situ hybridization (flow-FISH technique)Relationship between metalloprotease expression in tumour and stromal cells and aggressive behaviour in prostate carcinoma: Simultaneous high-throughput study of multiple metalloproteases and their inhibitors using tissue array analysis of radical pThe EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tablesPolyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinomaMyopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer[A challenge that is worth it]Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinomaEditorial Comment to External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle inMolecular classification of non-muscle-invasive bladder cancer (pTa low-grade, pT1 low-grade, and pT1 high-grade subgroups) using methylation of tumor-suppressor genes
P50
Q31133830-78F20585-A5EE-458A-9280-93C773D72042Q44216006-5213EF7E-D42F-494F-8D22-2DBB6BB625C4Q45816848-22A297B3-47ED-495C-B73D-11FE212F441FQ53189118-D4323CE9-788F-45B6-9A26-F5CA6CCADBBAQ79507655-A99726E9-704E-47F3-8352-9DDFC8F1FD1CQ79758612-A262AF00-0E27-4BAE-944C-9B07DF9EBF08Q81063462-273C9FB2-FFED-4733-8714-789BDD0E3729Q81864820-4CFB8311-9C67-4696-AFF9-BFC7C60CC5C9Q83228313-6B4C4D59-EDE1-402C-982C-215C1B57318FQ84215941-EB630664-B4AD-4DC2-BE92-9C05392F1105Q84342638-16643EF1-27B7-4E7A-95EC-6A7C3082C472Q84773019-2805A8F0-5B19-4AF5-9AB7-030C2B8DCEF3Q86347500-5DD33589-B1C8-4E7A-A99A-CC20831B5944Q86851692-34EC302D-F8AA-4ADD-BE05-894A1FB50D1CQ87467741-2136268D-1D03-49CD-AF98-8F8316E7C961Q88223989-0A8C03CB-1223-4918-9B0E-5F50E2FB1871
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Jesus Fernandez-Gomez
@en
Jesus Fernandez-Gomez
@nl
type
label
Jesus Fernandez-Gomez
@en
Jesus Fernandez-Gomez
@nl
prefLabel
Jesus Fernandez-Gomez
@en
Jesus Fernandez-Gomez
@nl
P31
P496
0000-0002-0804-5452